

## **Small-quantity lipid-based nutrient supplements for prevention of child malnutrition and promotion of healthy development: Overview of individual participant data meta-analysis and programmatic implications**

Kathryn G. Dewey, Christine P. Stewart, K. Ryan Wessells, Elizabeth L. Prado, Charles D. Arnold

Institute for Global Nutrition and Department of Nutrition, University of California, Davis, Davis, CA, USA (KGD, CPS, KRW, ELP, CDA)

Corresponding Author: Kathryn G. Dewey, Department of Nutrition, University of California, One Shields Ave., Davis, CA 95616; 530 752 0851; [kgdewey@ucdavis.edu](mailto:kgdewey@ucdavis.edu)

Sources of Support: Bill & Melinda Gates Foundation OPP49817

Short running head: Overview of SQ-LNS IPD meta-analysis

Abbreviations: AGP, α-1-acid glycoprotein; BMI, body-mass index; CRP, C-reactive protein; Hb, hemoglobin; HCZ, head circumference z-score; iLiNS, International Lipid-based Nutrient Supplements Project; IPD, individual participant data; IYCF, infant and young child feeding; LAZ, length-for-age z-score; LNS, lipid-based nutrient supplement; MNP, multiple micronutrient powder; MUAC, mid-upper arm circumference; MUACZ, mid-upper arm circumference z-score; RBP, retinol binding protein; RDNS, Rang-Din Nutrition Study; RUTF, ready-to-use therapeutic food; SBCC, social and behavior change communication; SES, socio-economic status; SQ-LNS, small-quantity lipid-based nutrient supplements; WASH, water sanitation and hygiene; WAZ, weight-for-age z-score; WLZ, weight-for-length z-score

Registry and registry number for systematic reviews or meta-analyses: Registered at

[www.crd.york.ac.uk/PROSPERO](http://www.crd.york.ac.uk/PROSPERO) as CRD42019146592, CRD42020159971 and

CRD42020156663 on November 19, 2019 and April 28 2020.

Data described in the manuscript, code book, and analytic code will not be made available because they are compiled from 14 different trials, and access is under the control of the investigators of each of those trials.

1    **Abstract**

2    Small-quantity lipid-based nutrient supplements (SQ-LNS) were designed to provide multiple  
3    micronutrients within a food base that also provides energy, protein and essential fatty acids, and  
4    were targeted towards the prevention of malnutrition in low- and middle-income countries.  
5    Previous meta-analyses have demonstrated beneficial effects of SQ-LNS on child growth,  
6    anemia and mortality. To further examine efficacy and effectiveness of SQ-LNS, and explore  
7    study-level and individual-level modifiers of the effects, we conducted an individual participant  
8    data (IPD) meta-analysis of 14 randomized controlled trials of SQ-LNS provided to infants and  
9    young children 6 to 24 mo of age ( $n > 37,000$ ). We examined growth, development, anemia and  
10   micronutrient status outcomes. Children who received SQ-LNS had a 12-14% lower prevalence  
11   of stunting, wasting and underweight, were 16-19% less likely to score in the lowest decile for  
12   language, social-emotional, and motor development, and had a 16% lower prevalence of anemia  
13   and 64% lower prevalence of iron-deficiency anemia, compared to control group children. For  
14   most outcomes, beneficial effects of SQ-LNS were evident regardless of study-level  
15   characteristics including region, stunting burden, malaria prevalence, sanitation, water quality,  
16   duration of supplementation, frequency of contact or average reported compliance with SQ-LNS.  
17   For certain outcomes, targeting based on population-level socioeconomic status or undernutrition  
18   may be worthwhile, as the benefits of SQ-LNS for iron status, anemia and child development  
19   were larger in sub-groups with a greater potential to benefit. A greater impact of SQ-LNS might  
20   be possible by co-packaging it with interventions that reduce constraints on response, such as  
21   prevention and control of pre-and postnatal infections, improving maternal nutrition, improving  
22   health care access, and promotion of early child development. Policy-makers and program  
23   planners should consider including SQ-LNS in strategies to reduce child mortality, stunting,

24 wasting, anemia, iron deficiency and developmental impairments. This study was registered at  
25 [www.crd.york.ac.uk/PROSPERO](http://www.crd.york.ac.uk/PROSPERO) as CRD42019146592, CRD42020159971 and  
26 CRD42020156663.

27

28 **Keywords:** Stunting, wasting, undernutrition, anemia, micronutrients, iron status, child  
29 development, complementary feeding, nutrient supplements, home fortification

30

31     **Introduction**

32     Millions of infants and young children in low- and middle-income countries are vulnerable to  
33     undernutrition and impaired neurobehavioral development (1-3). Globally, 21.3% (144 million)  
34     of children under 5 y of age were stunted and 6.9% (47 million) were wasted in 2019 (2).

35     Deficiencies of micronutrients such as iron, zinc, vitamin A and vitamin B<sub>12</sub> are widespread,  
36     particularly among children under 2 y of age, as a consequence of low micronutrient stores at  
37     birth, inadequate dietary intake of bioavailable micronutrients, and increased micronutrient  
38     requirements due to infection or malabsorption (4, 5). It is estimated that 250 million children  
39     under 5 y of age (43%) are at risk of not fulfilling their developmental potential (3), and this is  
40     linked to inadequate nutrient intake in early life (6, 7).

41

42     The causes of undernutrition and impaired development are complex and multi-factorial (8-13),  
43     and thus the impact of interventions that focus solely on improving nutrition may be limited (10,  
44     14). Although dietary interventions by themselves may not be sufficient to eliminate these  
45     adverse outcomes, they are a necessary element of strategies aimed at children under 2 y of age,  
46     given that inadequate intakes of key nutrients during the complementary feeding period from 6 to  
47     24 mo of age are highly prevalent (8). Improved dietary quality via selection of nutrient-rich  
48     complementary foods is the first priority (15, 16), but the cost may be prohibitive for low-income  
49     households (17, 18). Various types of fortified products have thus been designed to fill nutrient  
50     gaps during the period of complementary feeding, such as fortified blended foods, micronutrient  
51     powders (MNP) and lipid-based nutrient supplements (LNS) (19).

52

53 During the past 10 y there has been a rapid expansion of research to evaluate the efficacy and  
54 effectiveness of LNS in various settings, including meta-analyses of effects of prenatal LNS on  
55 birth outcomes (20), and of LNS for children on multiple outcomes (21) including mortality (22).  
56 In the meta-analysis of LNS given during the period of complementary feeding by Das et al.  
57 (21), 17 trials were included, 13 of which provided small-quantity LNS (SQ-LNS) in at least one  
58 arm (the other trials provided larger quantities of LNS). The authors reported positive results for  
59 prevention of stunting, wasting and anemia; too few studies were available for child development  
60 and micronutrient status outcomes. Although that meta-analysis included some analyses  
61 disaggregated by study characteristics, the authors did not conduct analyses stratified by  
62 individual-level characteristics.

63  
64 Since the 2019 meta-analysis by Das et al. (21), additional trials of SQ-LNS have been  
65 completed. To examine the current body of evidence relevant to SQ-LNS, and explore reasons  
66 for heterogeneity in results, we conducted an individual participant data (IPD) meta-analysis of  
67 randomized controlled trials of SQ-LNS provided to infants and young children 6 to 24 mo of  
68 age. Our objectives were to 1) generate pooled estimates of the effect of SQ-LNS on outcomes in  
69 3 different domains: a) growth, b) development and c) anemia and micronutrient status, and 2)  
70 identify study-level and individual-level modifiers of the effect of SQ-LNS on those outcomes.  
71 Identification of subgroups of infants and young children who experience greater benefits from  
72 SQ-LNS, or are more likely to respond to the intervention, may be useful in informing the  
73 development of public health programs and policies (14). This overview provides a brief history  
74 of the development and evaluation of SQ-LNS, a synopsis of the methods of the IPD meta-  
75 analyses and the trials included, and a synthesis of the results including discussion of the

76 programmatic and policy implications. Three other papers in this supplement report the detailed  
77 methods and results for each of the 3 outcome domains (23-25).

78

79 **Development and evaluation of SQ-LNS**

80 In the late 1990s, the first ready-to-use therapeutic food (RUTF) for treating severe malnutrition  
81 (Plumpy'nut) was developed, based on embedding micronutrients in a fat-based matrix. This  
82 technology allows the product to have a low water activity, which is critical because it inhibits  
83 the growth of harmful microorganisms without refrigeration, permitting treatment in outpatient  
84 settings. Community-based management of severe malnutrition using RUTF subsequently  
85 became widespread. While this revolutionized strategies for *treatment* of malnutrition, there  
86 were limited options with regard to effective strategies for *prevention* of malnutrition. To address  
87 the latter need, SQ-LNSs were developed based on the same type of food-based matrix used for  
88 RUTF (including vegetable oil, peanut paste and milk powder), but using a much smaller  
89 quantity of food, typically about 4 teaspoons (~100-120 kcal) per day (26). The food base  
90 provides energy, protein, and essential fatty acids; together with the multiple micronutrients  
91 added via fortification, the combination addresses multiple potential nutritional deficiencies.

92

93 The target quantity of food in SQ-LNS designed for infants and young children was small for  
94 several reasons. First, it is important to avoid displacing breast milk and locally available  
95 nutrient-rich foods. The energy needed from complementary foods, assuming average breast  
96 milk intakes, is only ~200 kcal at 6–8 mo, ~300 at 9–11 mo and ~550 kcal at 12–23 mo of age.  
97 The proportions of these energy needs provided by SQ-LNS are approximately one-half at 6–8  
98 mo, one-third at 9–11 mo, and one-fifth at 12–23 mo, leaving room for other complementary  
99 foods in the diet. Second, the small quantity of the daily ration of SQ-LNS makes it likely that

100 the child can consume the entire ration in one day, thereby receiving the intended doses of the  
101 micronutrients and essential fatty acids. With a larger quantity, such as medium-quantity LNS  
102 (typically 250-500 kcal/d; (26)), a substantial amount may be left unconsumed (27), particularly  
103 by infants 6-12 mo of age. Third, the daily ration of SQ-LNS can easily be mixed with other  
104 foods (and thus SQ-LNS is considered a type of home fortification product (28)), or consumed as  
105 is, allowing for flexibility in feeding practices. Last, the cost of production and transport of  
106 LNS, and the feasibility of distribution via platforms such as community health workers, is  
107 related to the quantity per recipient, so SQ-LNS is a lower-cost option than other fortified  
108 products designed for a larger daily ration.

109

110 The first trials evaluating SQ-LNS were published in 2007-2008, and results were promising  
111 with regard to prevention of linear growth faltering in Ghana (29) and of severe stunting in  
112 Malawi (30). Subsequently, the International Lipid-based Nutrient Supplements (iLiNS) Project  
113 (<https://ilins.ucdavis.edu/>) was funded by the Bill & Melinda Gates Foundation to develop  
114 several modified formulations of SQ-LNS (including a version for pregnant and lactating  
115 women), conduct large randomized controlled efficacy trials in 3 countries in Africa, conduct  
116 socioeconomic studies of SQ-LNS, and coordinate efforts among stakeholders. For the latter  
117 objective, the iLiNS Project facilitated the LNS Research Network between 2009 and 2015 to  
118 promote exchange of information and experience among researchers and practitioners. These  
119 efforts accelerated research on SQ-LNS in a variety of contexts by numerous investigators, both  
120 within and outside of the iLiNS Project. This work included studies of acceptability and  
121 adherence, trials assessing efficacy and effectiveness for improving a range of different

122 outcomes among infants and young children, as well as pregnant and lactating women, and  
123 studies on costs and willingness to pay for SQ-LNS.

124  
125 Researchers designing trials to evaluate SQ-LNS have recognized that provision of supplements  
126 needs to be accompanied by appropriate messages. These include not just information about the  
127 use and storage of SQ-LNS but also messages to emphasize recommended infant and young  
128 child feeding (IYCF) practices. These messages have typically included promotion of  
129 breastfeeding, introduction of complementary foods at 6 mo of age, and recommendations  
130 regarding dietary diversity and feeding nutrient-rich complementary foods. These messages have  
131 usually been provided to both intervention and control groups, to reinforce the normal IYCF  
132 messages already promoted in the study location. Some studies have gone further by providing  
133 expanded social and behavior change communication (SBCC) on IYCF. Thus, provision of SQ-  
134 LNS generally occurs within an overall context to improve IYCF, not as an isolated intervention  
135 solely focused on delivering a product.

136  
137 **SQ-LNS IPD meta-analysis**  
138 *Overview of methods*  
139 The IPD meta-analysis presented in the accompanying articles is based on pooled data from 14  
140 randomized controlled trials of SQ-LNS. This work followed best practices for pre-registration,  
141 transparency, and reproducibility, with protocols and statistical analysis plans posted online  
142 (osf.io/ymsfu and at PROSPERO CRD42019146592, CRD42020159971 and CRD42020156663)  
143 (31-34). The trials were identified beginning with those published in a recent Cochrane Review  
144 (21), and supplemented with additional studies identified through a systematic review of studies

145 published through September 2019. Investigators who led trials meeting the eligibility criteria  
146 shown in **Box 1** were invited to contribute data and participate in the analysis.

147

148 The main comparison of interest was the provision of SQ-LNS (<~125 kcal/d, with or without  
149 co-interventions) vs. provision of no intervention or an intervention without any type of LNS or  
150 other child supplement. For trials with multiple relevant SQ-LNS interventions (e.g., varying  
151 dosages or formulations of SQ-LNS in different arms), or that combined provision of SQ-LNS  
152 with other non-nutritional interventions (i.e., water, sanitation and hygiene (WASH)), all arms  
153 that provided SQ-LNS were combined into one group. All non-LNS arms were combined into a  
154 single comparator (“control”) group for each trial [excluding intervention arms that received  
155 non-LNS child supplementation, e.g., MNP, fortified-blended food]. For trials that provided both  
156 maternal and child LNS, we conducted analyses both with (“all-trials analysis”) and without  
157 (“child-LNS-only”) the maternal LNS arms. The main effects did not differ between these two  
158 analyses by more than 20% for continuous outcomes or by 0.05 for prevalence ratios, so the  
159 results of the all-trials analyses are presented as the principal findings.

160

161 We conducted several pre-specified sensitivity analyses: 1) separate comparisons within multi-  
162 component intervention trials, such that the SQ-LNS vs. no SQ-LNS comparisons were  
163 conducted separately between pairs of arms with the same non-nutrition components (e.g. SQ-  
164 LNS+WASH vs. WASH; SQ-LNS vs. Control), 2) exclusion of passive control arms, i.e.,  
165 control group participants received no intervention and had no contact with project staff between  
166 baseline and endline, and 3) exclusion of intervention arms with SQ-LNS formulations that did  
167 not include both milk and peanut.

168 Three types of statistical analyses were conducted to separately investigate 1) full sample  
169 treatment effects, 2) effect modification by study-level characteristics, and 3) effect modification  
170 by individual-level characteristics. For all 3 sets of analyses, we used a two-stage approach  
171 following a complete-case intention-to-treat framework. We used bivariate meta-regression  
172 modeling to examine effect modification by study-level characteristics. We modeled effect  
173 modification by individual-level characteristics within each study, and then pooled the estimates.  
174 Potential effect modifiers examined are shown in **Table 1**.

175

176 *Trials included*

177 We identified 15 trials that met our inclusion criteria, 14 of which provided individual participant  
178 data and were included in the analyses (**Table 2**) (29, 35-48). Investigators for one trial were  
179 unable to participate (49). One trial was designed *a priori* to present results separately for HIV-  
180 exposed and HIV-unexposed children and is presented as two separate comparisons in all  
181 analyses (47, 48). Similarly, the two PROMIS trials in Burkina Faso and Mali each included an  
182 independent longitudinal cohort and repeated (at baseline and endline) cross-sectional samples,  
183 so the longitudinal and cross-sectional results are presented as separate comparisons for each  
184 trial (39, 46).

185

186 The 14 trials in these analyses were conducted in Sub-Saharan Africa (10 trials in 7 countries),  
187 Bangladesh (3 trials), and Haiti (1 trial), and included a total of 37,066 infants and young  
188 children. Most trials began child supplementation with SQ-LNS at 6 mo of age and the intended  
189 duration ranged from 6 to 18 mo of supplementation; four trials included intervention arms that

190 also provided SQ-LNS to mothers during pregnancy and the first 6 mo postpartum (36, 40, 43,  
191 44). All trials provided a peanut- and milk-based SQ-LNS in at least one of the arms.

192

193 Six trials were conducted within existing community-based or clinic-based programs (36, 39, 41,  
194 43, 46-48); in the other trials, all activities were conducted by research teams. Seven trials  
195 provided minimal messaging on IYCF other than reinforcing the normal IYCF messages already  
196 promoted in that setting (29, 36, 38, 40, 41, 44, 45), and 7 trials provided expanded SBCC on  
197 IYCF that went beyond the usual messaging, either in just the SQ-LNS intervention arms (37,  
198 39, 42, 47, 48) or in all arms including the non-SQ-LNS control arm (35, 43, 46). Three trials  
199 included arms with WASH interventions (37, 42, 47, 48). Most trials included an active control  
200 arm (i.e., similar contact frequency as for intervention arms) but 3 included only a passive  
201 control arm (29, 37, 38).

202

203 The 14 study sites were highly diverse in terms of study-level characteristics including stunting  
204 burden, malaria prevalence, water quality, sanitation and aspects of study design such as duration  
205 of supplementation, frequency of contact and average compliance with SQ-LNS. There was also  
206 wide variation within and between studies in maternal, child and household characteristics. This  
207 provided heterogeneity for exploration of potential effect modifiers.

208

209 *Synthesis of results and programmatic implications*

210 Main effects of SQ-LNS

211 Overall, when combining data from all of the trials, we found significant effects of SQ-LNS  
212 across all three outcome domains (**Table 3**). Children who received SQ-LNS had a 12-14%

213 lower prevalence of stunting, wasting and underweight (23), were 16-19% less likely to score in  
214 the lowest decile for language, social-emotional, and motor development (24), and had a 16%  
215 lower prevalence of anemia and 64% lower prevalence of iron-deficiency anemia (25), compared  
216 to control children who did not receive SQ-LNS. These findings add to those of a recently  
217 published meta-analysis of many of these same trials reporting a 27% lower risk of mortality  
218 between 6 and 24 mo of age (22).

219

220 This IPD meta-analysis includes nearly 3 times as many participants as the meta-analysis by Das  
221 et al. (21), even though we restricted the analysis to trials that provided SQ-LNS. Our new  
222 estimates for wasting and underweight are similar to those of Das et al., but the new estimate for  
223 stunting (12% relative reduction) is larger than previously reported (7% reduction). For child  
224 development outcomes, Das et al. provided a narrative review of effects, but were not able to  
225 generate pooled estimates. With regard to anemia, Das et al. reported a relative reduction of  
226 21%; our 16% reduction is somewhat lower than that, but we defined anemia as hemoglobin <  
227 110 g/L whereas Das et al. examined anemia as defined by trialists. In addition, we report 56-  
228 64% reductions in iron deficiency and iron-deficiency anemia, which were not reported in the  
229 meta-analysis by Das et al. The larger reduction in prevalence of iron-deficiency anemia as  
230 compared to all-cause anemia reflects the complex etiology of anemia; supplementation is likely  
231 to prevent only the fraction of anemia attributable to nutritional causes.

232

233 The overall effects of SQ-LNS on the growth and development outcomes were modest.  
234 However, the effects were generally more consistent, and for some outcomes more substantial,  
235 compared to other nutrition interventions for children under 2 y of age, such as nutrition

236 education, micronutrient supplementation or fortification, and fortified blended foods (50-54).  
237 Many studies have examined the impacts of behavior change interventions focused on improving  
238 complementary feeding practices. A 2018 Cochrane review concluded that such interventions are  
239 effective at improving reported feeding practices, but there was insufficient evidence to draw  
240 conclusions with respect to effects on growth, development, anemia, or micronutrient status (51).  
241 Within our IPD analysis, three trials had direct comparisons of LNS+IYCF behavior change  
242 versus IYCF behavior change alone: the JiVitA-4 trial in Bangladesh (35), the PROMIS study in  
243 Mali (46), and the Mahay study in Madagascar (43). In 2 of these 3 trials (JiVitA-4 and  
244 PROMIS-Mali), the children in the LNS intervention arm had improved growth, hemoglobin and  
245 motor development scores compared to children in the IYCF-only arm.

246

247 Effects of SQ-LNS on anemia and iron deficiency were similar to those reported in a recent  
248 meta-analysis of MNP (18% reduction in anemia and 53% reduction in iron deficiency; (55)).  
249 However, that review demonstrated no effects of MNP on child growth and there was  
250 insufficient evidence to evaluate effects on child development or mortality.

251

252 Compared to interventions promoting responsive care and provision of learning opportunities for  
253 young children, effects of SQ-LNS on mean scores for child development were substantially  
254 smaller: pooled effect sizes for the former ranged from 0.39 to 0.49 SD higher scores of  
255 language, social-emotional, and motor development (56, 57) compared to 0.07 to 0.08 SD higher  
256 scores for those domains in the SQ-LNS IPD analysis. However, the former trials did not report  
257 estimates for the prevalence of children scoring below a given cut-off in each domain, so we  
258 cannot directly compare results with the impact of SQ-LNS on the percentage of children scoring

259 in the lowest decile (relative reductions of 16-19%). Many of the responsive care and learning  
260 opportunities studies did not measure indicators of child growth; however, among those that did,  
261 there was little evidence of effect (56). Thus, the two types of interventions may be  
262 complementary.

263

264 **Effect modification**

265 Each of the accompanying papers presents detailed information on the effect modification  
266 results. For most of the outcome domains, effect modification was examined in 3 ways: as the  
267 mean difference in the continuous outcome (e.g., LAZ) between SQ-LNS and control groups, as  
268 the prevalence ratio between the 2 groups for a binary outcome (e.g., the relative risk of  
269 stunting), and as the difference in absolute prevalence between the 2 groups for a binary outcome  
270 (e.g., the percentage point difference in prevalence of stunting). We considered all 3 types of  
271 outcomes together and in reference to 3 different theoretical scenarios: potential to benefit,  
272 potential to respond, and cutoff effects.

273       **Potential to benefit:** One possibility is that certain subgroups of children may be more  
274 likely to benefit from the SQ-LNS intervention, perhaps due to greater nutritional deficits at  
275 baseline (14). This is illustrated in **Figure 1A**. The children with greater nutritional or  
276 developmental deficits in subgroup a-1 are shown here as being slightly smaller and thinner  
277 compared to the children in subgroup a-2. When SQ-LNS is provided, the children in subgroup  
278 a-1 may benefit more. Our interpretation in these cases is that there were greater benefits to those  
279 who needed it most.

280       **Potential to respond:** Another possibility is that certain subgroups may differ in their  
281 potential to respond to the intervention (14), as a result of constraints such as infection or

282 inflammation, caregiver time or resources, or chronic stress. In **Figure 1B**, subgroup b-2 has  
283 greater constraints whereas subgroup b-1 has no such constraints. In this case, we might expect  
284 to see a greater response to supplementation in subgroup b-1.

285         *Cutoff effects:* Effect modification results may differ as an artifact of where the  
286 continuous outcome distribution falls with respect to the cutoff value for a binary variable. In  
287 **Figure 2**, subgroup B has a higher proportion of observations clustered near the cutoff value.  
288 Assuming similar shifts in the means of the distributions within both subgroups in response to  
289 the intervention, a very different proportion of children cross the cutoff value threshold. In this  
290 example, a greater proportion of children in subgroup B would cross that threshold as compared  
291 to subgroup A. Thus, there may be statistically significant effect modification for a binary  
292 outcome measure, but not for the corresponding continuous outcome measure. In these  
293 situations, if there is no significant effect modification for the continuous outcome, we interpret  
294 the results as evidence that both subgroups benefit and respond similarly. For this reason, we  
295 have not highlighted these examples for further discussion here, but they are described in the  
296 accompanying papers (23-25).

297  
298 For growth and development outcomes, most of the study-level characteristics and aspects of  
299 study design did not significantly modify the effects of SQ-LNS; the exceptions were stunting  
300 and anemia burdens, which were related to the impact of SQ-LNS on child development  
301 outcomes. For anemia and iron deficiency, several study characteristics (region, anemia burden,  
302 malaria prevalence, and prevalence of inflammation) and aspects of study design (duration of  
303 supplementation, iron dose in SQ-LNS, and average compliance with SQ-LNS) appeared to  
304 modify the effects of SQ-LNS. For all outcomes, there was significant effect modification by

305 individual-level characteristics, but the characteristics that appeared to be important varied  
306 considerably depending on the type of outcome. In the paragraphs that follow, we discuss effect  
307 modifiers that were common across multiple outcome domains or that might have programmatic  
308 implications, using the concepts of potential to benefit and potential to respond described above  
309 to interpret the findings.

310

311 For two characteristics, child-level acute malnutrition and country-level anemia burden, the  
312 results suggested that populations with greater nutritional deficits may have greater potential to  
313 benefit from supplementation. Among children acutely malnourished at baseline, plasma ferritin  
314 concentration increased by 85% and language, social-emotional, and motor development scores  
315 increased by approximately 0.3 standard deviations in the SQ-LNS vs. control groups. In  
316 contrast, among children not acutely malnourished, there was a smaller, though still significant  
317 impact on plasma ferritin (47% increase) and an increase of only ~0.1 SD in developmental  
318 scores. Similarly, in sites with a higher anemia burden, there were larger differences in mean  
319 hemoglobin (+4.9 in SQ-LNS vs. control groups in high anemia burden sites compared to +2.5  
320 g/L in low anemia burden sites), and larger reductions in the prevalence of moderate-to-severe  
321 anemia (-13 vs. -4 percentage points) and lowest decile of motor scores (25% vs 12%).

322

323 Effect modification by two other characteristics, household socioeconomic status (SES) and  
324 study-level stunting burden, suggested that children experiencing greater levels of poverty  
325 benefitted more with respect to the effect of SQ-LNS on child development. Such children may  
326 be at greater risk of developmental impairment (24) and therefore may have a greater potential to  
327 benefit developmentally from supplementation. The mean effects of SQ-LNS on language,

328 social-emotional, and motor development scores in low-SES households were +0.06 to +0.12  
329 SD, compared to little to no effects among children in higher SES households. Similarly, in sites  
330 with a high stunting burden, language, social-emotional, and motor development scores were  
331 +0.08 to +0.13 SD higher in the SQ-LNS vs. control groups; in contrast, there were no effects on  
332 these outcomes in settings with a low stunting burden. While these differences were apparent for  
333 the development outcomes, SES and stunting burden generally did not significantly modify the  
334 effects of SQ-LNS on growth, anemia, or iron status outcomes.

335  
336 Child sex was an effect modifier of the effect of SQ-LNS on growth and anemia, with stronger  
337 effects among girls than boys. Among girls, SQ-LNS reduced the prevalence of stunting by 16%  
338 (vs. 9% among boys), wasting by 21% (vs. 10%), low MUAC by 27% (vs. 7%), small head size  
339 by 15% (vs. 4%) and anemia by 18% (vs. 13%), though the latter difference was likely due to the  
340 cutoff effect. Girls had higher mean anthropometric z-scores and hemoglobin concentrations  
341 than boys, which suggests that they did not have a greater potential to benefit from the  
342 supplementation. Rather, they may have had a greater potential to respond. Boys are at greater  
343 risk of morbidity and mortality in early life and may be more vulnerable to environmental  
344 stressors (58), which could constrain their response to a nutrition intervention. However, there  
345 were significant positive effects of SQ-LNS on mean z-scores for growth, hemoglobin  
346 concentration and indicators of iron status among both boys and girls. Additionally, child sex did  
347 not modify the effect of SQ-LNS on any indicators of child development. Thus, both boys and  
348 girls benefitted from the intervention.

349

350 Child birth order and maternal age both modified the effects of SQ-LNS on more than one  
351 outcome domain. Effects of SQ-LNS were greater among later-born children (i.e., those with at  
352 least one older sibling) than among first-born children with regard to stunting (13% vs 9%  
353 relative reduction among later-born vs. first-born children, respectively), underweight (17% vs  
354 6% reduction), low MUAC (23% vs 5% reduction), anemia (12 vs 7 percentage point reduction),  
355 and several continuous outcomes (mean WAZ, MUACZ, motor and fine motor scores,  
356 hemoglobin, and ferritin concentrations). Similarly, effects of SQ-LNS were greater among  
357 children born to older mothers than among those born to younger mothers with regard to anemia  
358 (17% vs 13% relative reduction) and mean motor and fine motor scores. Birth order and maternal  
359 age are positively correlated, so it is difficult to disentangle which factor is the most likely driver  
360 of these differences. Later-born children have at least one older sibling with whom they may  
361 compete for resources, making them potentially more vulnerable to malnutrition. In fact, we  
362 observed lower mean hemoglobin concentration and a greater prevalence of stunting and  
363 underweight among later-born (vs first-born) children in the control groups in the IPD analysis,  
364 suggesting that they have a greater potential to benefit from nutritional supplementation.

365  
366 Maternal education and depressive symptoms also appeared to modify the effect of SQ-LNS on  
367 growth and development, but in seemingly disparate ways. Among children whose mothers had  
368 higher education or less depressive symptoms, there were greater effects of SQ-LNS on growth.  
369 This may reflect a greater potential to respond to the intervention. Such mothers may have had  
370 greater autonomy and agency, and therefore may have been better able to adhere to advice  
371 regarding the recommended frequency or dosage of supplementation. By contrast, among  
372 children whose mothers had lower education, there were larger beneficial effects of SQ-LNS on

373 child development. Other studies have reported that maternal education is associated with  
374 developmental delays (59), and therefore these children may have lagged behind their peers and  
375 had greater room for improvement, with greater potential to benefit from an intervention.

376

377 Effect modification by season of assessment was significant for wasting and iron status, although  
378 the direction of the relationship differed by outcome. Specifically, there were greater effects of  
379 SQ-LNS on the prevalence of wasting among children assessed during the dry season (22%  
380 reduction) compared to children assessed during the rainy season (8% reduction), which may  
381 reflect a greater potential to respond in the dry season due to a lower burden of infections. On the  
382 other hand, effects of SQ-LNS on iron status were greater when it was measured during the rainy  
383 season, with an increase of 74% in ferritin concentration and a decrease of 63% in the prevalence  
384 of iron deficiency relative to the control groups. In the dry season, a benefit of SQ-LNS was still  
385 apparent (44% increase in ferritin and 47% reduction in the prevalence of iron deficiency), but  
386 the effect size was smaller. These results do not suggest that SQ-LNS interventions should be  
387 targeted to one season or another, but they have important implications with regard to  
388 interpreting results from evaluations, particularly if such studies have not been conducted  
389 longitudinally across a full calendar year. It is also important to note that the data included in the  
390 IPD meta-analysis were generally based on cross-sectional outcome assessments, which do not  
391 capture the multiple episodes of wasting/acute malnutrition, micronutrient deficiency, or anemia  
392 that may occur throughout the study period. In the PROMIS study in Mali, for example, the  
393 longitudinal prevalence of acute malnutrition was much higher than the cross-sectional  
394 prevalence, and the SQ-LNS intervention reduced the former by 29% but had no significant  
395 impact on the latter (46).

396

397 Finally, greater effects of SQ-LNS on iron status and anemia were observed among children  
398 without inflammation at the time of assessment. This may reflect a greater potential to respond  
399 to a nutrition intervention among children without inflammation, who are likely to experience  
400 less inhibition of iron absorption or sequestration of circulating iron (60, 61). Despite this  
401 difference, significant positive effects of SQ-LNS on these outcomes were apparent in both sub-  
402 groups, with and without inflammation.

403

#### 404 **Conclusions**

405 In summary, the evidence suggests that there are important benefits of SQ-LNS for child  
406 survival, growth, anemia, iron status, and child development. It must be noted that SQ-LNS is  
407 not a stand-alone intervention, as it should always be accompanied by messaging to reinforce  
408 IYCF recommendations, including a diverse diet with healthy foods from the key food groups.  
409 Nonetheless, it appears to play a protective role when access to nutrient-rich foods is limited for  
410 economic or other reasons. Of course, the benefits of SQ-LNS must be weighed against the  
411 potential benefits of alternative interventions and the costs of delivering each type of  
412 intervention. At present, however, we are not aware of any other intervention that has a  
413 demonstrated impact on all of the outcomes mentioned above.

414

415 The IPD meta-analysis included >37,000 children from a wide range of settings. For most  
416 outcomes, beneficial effects of SQ-LNS were evident regardless of region, stunting burden,  
417 malaria prevalence, sanitation, water quality, duration of supplementation, frequency of contact  
418 or average reported compliance with SQ-LNS. Moreover, 6 of the 14 trials were conducted

419 within existing community-based or clinic-based programs, so the evidence represents the  
420 continuum from efficacy to effectiveness trials. The sensitivity analyses demonstrated very  
421 similar results, indicating that the findings are robust. One limitation was that Bangladesh was  
422 the only country represented in the Southeast Asia Region and Haiti was the only country  
423 represented in Latin America and the Caribbean, so additional data from countries outside of  
424 Africa would be valuable.

425

426 The effect modification results suggest that for certain outcomes, targeting on the basis of  
427 population-level socioeconomic status or burden of undernutrition may be worth considering, as  
428 the benefits of SQ-LNS for iron status, anemia and child development were larger in sub-groups  
429 who had a greater potential to benefit from the intervention. The results also suggest that a  
430 greater impact of SQ-LNS might be obtained by co-packaging it with interventions that alleviate  
431 constraints on response, such as the prevention and control of pre-and postnatal infections;  
432 improving maternal nutrition; improving access to health care, including mental health care for  
433 women; and promoting early child development interventions that promote responsive  
434 caregiving.

435

436 The selection of intervention(s) for a given population should be based on the needs of the  
437 population, the goals of the program, as well as cost:benefit considerations. Although the latter is  
438 outside of the scope of this and the accompanying papers, work is under way to understand these  
439 economic dimensions. In the meantime, we recommend that policy-makers and program  
440 planners consider including SQ-LNS in the mix of interventions to reduce child mortality,  
441 stunting, wasting, anemia, iron deficiency and developmental impairments. It is one of the few

442 interventions that can help to achieve multiple Sustainable Development Goal targets  
443 simultaneously, as well as support the three pillars of the United Nations' 2016-2030 Global  
444 Strategy for Women's, Children's and Adolescents' health (62): surviving (ending preventable  
445 deaths), thriving (ensuring health and well-being) and transforming (expanding enabling  
446 environments).

447

448 **Acknowledgments**

449 We thank all of the co-investigators, collaborators, study teams, participants and local  
450 communities involved in the trials included in these analyses. These trials benefitted from the  
451 contributions of many partner organizations, including: icddr,b (JiVitA-4, Rang-Din Nutrition  
452 Study and WASH Benefits trial in Bangladesh); the World Food Program (JiVitA-4 trial in  
453 Bangladesh); the Health District of Dandé and the relevant local health-care authorities (iLiNS-  
454 ZINC trial in Burkina Faso); AfricSanté and Helen Keller International (PROMIS trials in  
455 Burkina Faso and Mali); Ministry of Public Health and Population (Haiti trial); Innovations for  
456 Poverty Action and the Kenya Medical Research Institute (WASH-Benefits trial in Kenya);  
457 Unité Programme National de Nutrition Communautaire, Government of Madagascar, and  
458 World Bank Health and Nutrition and Population Global Practice (MAHAY trial in  
459 Madagascar); the Ministry of Health and Child Care in Harare, Chirumanzu and Shurugwi  
460 districts, and Midlands Province (SHINE trial in Zimbabwe); the International Lipid-based  
461 Nutrient Supplements Project Steering Committee (iLiNS Project trials); and Nutriset (for  
462 development of SQ-LNS). We thank Emily Smith for advice on IPD analysis methods.

463

464 The authors' responsibilities were as follows—KGD and CPS: drafted the manuscript with input  
465 from other coauthors; All authors read, contributed to, and approved the final manuscript.

466

467 Supported by Bill & Melinda Gates Foundation grant OPP49817 (to KGD). All authors report no  
468 conflicts of interest.

469

## References

1. Black RE, Victora CG, Walker SP, Bhutta ZA, Christian P, de Onis M, Ezzati M, Grantham-McGregor S, Katz J, Martorell R, et al. Maternal and child undernutrition and overweight in low-income and middle-income countries. *Lancet* 2013;382:427-51.
2. United Nations Children's Fund (UNICEF), World Health Organization, International Bank for Reconstruction and Development/The World Bank. Levels and trends in child malnutrition: Key Findings of the 2020 Edition of the Joint Child Malnutrition Estimates. Geneva: World Health Organization; 2020.
3. Black MM, Walker SP, Fernald LCH, Andersen CT, DiGirolamo AM, Lu C, McCoy DC, Fink G, Shawar YR, Shiffman J, et al. Early childhood development coming of age: science through the life course. *Lancet* 2017;389:77-90.
4. Bailey RL, West KP, Jr., Black RE. The epidemiology of global micronutrient deficiencies. *Ann Nutr Metab* 2015;66 Suppl 2:22-33.
5. United Nations Children's Fund (UNICEF). Improving Child Nutrition: The Achievable Imperative for Global Progress. New York, UNICEF, 2013. Available at: [https://www.unicef.org/publications/index\\_68661.html](https://www.unicef.org/publications/index_68661.html). Accessed on: 25 September 2020.
6. Barks A, Hall AM, Tran PV, Georgieff MK. Iron as a model nutrient for understanding the nutritional origins of neuropsychiatric disease. *Pediatr Res* 2019;85:176-82.
7. Grantham-McGregor S, Cheung YB, Cueto S, Glewwe P, Richter L, Strupp B, International Child Development Steering G. Developmental potential in the first 5 years for children in developing countries. *Lancet* 2007;369:60-70.
8. Stewart CP, Iannotti L, Dewey KG, Michaelsen KF, Onyango AW. Contextualising complementary feeding in a broader framework for stunting prevention. *Matern Child Nutr* 2013;9 Suppl 2:27-45.
9. Prendergast AJ, Humphrey JH. The stunting syndrome in developing countries. *Paediatr Int Child Health* 2014;34:250-65.
10. Millward DJ. Nutrition, infection and stunting: the roles of deficiencies of individual nutrients and foods, and of inflammation, as determinants of reduced linear growth of children. *Nutr Rev* 2017;30:50-72.
11. Harper KM, Mutasa M, Prendergast AJ, Humphrey J, Manges AR. Environmental enteric dysfunction pathways and child stunting: A systematic review. *PLoS Negl Trop Dis* 2018;12:e0006205.
12. Schoenbuchner SM, Dolan C, Mwangome M, Hall A, Richard SA, Wells JC, Khara T, Sonko B, Prentice AM, Moore SE. The relationship between wasting and stunting: a retrospective cohort analysis of longitudinal data in Gambian children from 1976 to 2016. *Am J Clin Nutr* 2019;110:498-507.
13. Black RE. Patterns of growth in early childhood and infectious disease and nutritional determinants. *Nestle Nutr Inst Workshop Ser* 2017;87:63-72.
14. Dewey KG. Reducing stunting by improving maternal, infant and young child nutrition in regions such as South Asia: evidence, challenges and opportunities. *Matern Child Nutr* 2016;12 Suppl 1:27-38.
15. PAHO/WHO (Pan American Health Organization/World Health Organization). 2003. Guiding principles for complementary feeding of the breastfed child. Washington, DC: PAHO.
16. United Nations Children's Fund (UNICEF). Improving young children's diets during the complementary feeding period. UNICEF Programming Guidance. New York: UNICEF, 2020.

17. Headey DD, Alderman HH. The relative caloric prices of healthy and unhealthy foods differ systematically across income levels and continents. *J Nutr* 2019;149:2020-33.
18. Miller V, Yusuf S, Chow CK, Dehghan M, Corsi DJ, Lock K, Popkin B, Rangarajan S, Khatib R, Lear SA, et al. Availability, affordability, and consumption of fruits and vegetables in 18 countries across income levels: findings from the Prospective Urban Rural Epidemiology (PURE) study. *Lancet Glob Health* 2016;4:e695-703.
19. Dewey KG, Vitta BS. Strategies for ensuring adequate nutrient intake for infants and young children during the period of complementary feeding. *Insight Issue No 7*, pp 14 Alive & Thrive Technical Brief: Washington DC 2013.
20. Das JK, Hoodbhoy Z, Salam RA, Bhutta AZ, Valenzuela-Rubio NG, Weise Prinzo Z, Bhutta ZA. Lipid-based nutrient supplements for maternal, birth, and infant developmental outcomes. *Cochrane Database Syst Rev* 2018;8:CD012610.
21. Das JK, Salam RA, Hadi YB, Sadiq Sheikh S, Bhutta AZ, Weise Prinzo Z, Bhutta ZA. Preventive lipid-based nutrient supplements given with complementary foods to infants and young children 6 to 23 months of age for health, nutrition, and developmental outcomes. *Cochrane Database Syst Rev* 2019;5:CD012611.
22. Stewart CP, Wessells KR, Arnold CD, Huybrechts L, Ashorn P, Becquey E, Humphrey JH, Dewey KG. Lipid-based nutrient supplements and all-cause mortality in children 6-24 months of age: a meta-analysis of randomized controlled trials. *Am J Clin Nutr* 2020;111:207-18.
23. Dewey KG, Wessells KR, Arnold CD, Prado EL, Abbeddou S, Adu-Afarwuah S, Ali H, Arnold BF, Ashorn P, Ashorn U, et al. Characteristics that modify the effect of small-quantity lipid-based nutrient supplementation on child growth: an individual participant data meta-analysis of randomized controlled trials. *Amer J Clin Nutr*, in this supplement.
24. Prado EL, Arnold CD, Wessells KR, Stewart CP, Abbeddou S, Adu-Afarwuah S, Arnold BF, Ashorn U, Ashorn P, Becquey E, et al. Small-quantity lipid-based nutrient supplements for children age 6-24 months: a systematic review and individual participant data meta-analysis of effects on developmental outcomes and effect modifiers. *Amer J Clin Nutr*, in this supplement.
25. Wessells K, Arnold C, Stewart C, Prado E, Abbeddou S, Adu-Afarwuah S, Arnold BF, Ashorn P, Ashorn U, Becquey E, et al. Characteristics that modify the effect of small-quantity lipid-based nutrient supplementation on child anemia and micronutrient status: an individual participant data metaanalysis of randomized controlled trials. *Amer J Clin Nutr*, in this supplement.
26. Arimond M, Zeilani M, Jungjohann S, Brown KH, Ashorn P, Allen LH, Dewey KG. Considerations in developing lipid-based nutrient supplements for prevention of undernutrition: experience from the International Lipid-Based Nutrient Supplements (iLiNS) Project. *Matern Child Nutr* 2015;11 Suppl 4:31-61.
27. Hemsworth J, Kumwenda C, Arimond M, Maleta K, Phuka J, Rehman AM, Vosti SA, Ashorn U, Filteau S, Dewey KG, et al. Lipid-based nutrient supplements increase energy and macronutrient intakes from complementary food among Malawian infants. *J Nutr* 2016;146:326-34.
28. Home Fortification Technical Advisory Group. Available at: <http://www.hftag.org>. Accessed on: 1 July 2020.
29. Adu-Afarwuah S, Lartey A, Brown KH, Zlotkin S, Briand A, Dewey KG. Randomized comparison of 3 types of micronutrient supplements for home fortification of complementary foods in Ghana: effects on growth and motor development. *Am J Clin Nutr* 2007;86:412-20.
30. Phuka JC, Maleta K, Thakwalakwa C, Cheung YB, Briand A, Manary MJ, Ashorn P. Complementary feeding with fortified spread and incidence of severe stunting in 6- to 18-month-old rural Malawians. *Arch Pediatr Adolesc Med* 2008;162:619-26.

31. Wessells KR, Stewart C, Arnold CD, Dewey K, Prado E. Modifiers of the effect of LNS provided to infants and children 6 to 24 months of age on growth, anemia, micronutrient status and development outcomes. Open Science Framework. Available from: <https://osf.io/ymsfu>.
32. Wessells K, Dewey K, Stewart C, Arnold C, Prado E. Modifiers of the effect of LNS provided to infants and children 6 to 24 months of age on growth outcomes: a systematic review and meta-analysis of individual participant data from randomized controlled trials in low-income and middle-income countries. PROSPERO 2019 CRD42019146592 Available from: [https://www.crd.york.ac.uk/prospero/display\\_record.php?ID=CRD42019146592](https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42019146592).
33. Wessells K, Prado E, Dewey K, Stewart C, C A. Modifiers of the effect of LNS provided to infants and children 6 to 24 months of age on developmental outcomes: a systematic review and meta-analysis of individual participant data from randomized controlled trials in low-income and middle-income countries. PROSPERO 2020 CRD42020159971 Available from: [https://www.crd.york.ac.uk/prospero/display\\_record.php?ID=CRD42020159971](https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020159971).
34. Wessells K, Dewey K, Stewart C, Arnold C, Prado E. Modifiers of the effect of LNS provided to infants and children 6 to 24 months of age on anemia and MN status outcomes: a systematic review and meta-analysis of individual participant data from randomized controlled trials in low-income and middle-income countries. PROSPERO 2020 CRD42020156663 Available from: [https://www.crd.york.ac.uk/prospero/display\\_record.php?ID=CRD42020156663](https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020156663).
35. Christian P, Shaikh S, Shamim AA, Mehra S, Wu L, Mitra M, Ali H, Merrill RD, Choudhury N, Parveen M, et al. Effect of fortified complementary food supplementation on child growth in rural Bangladesh: a cluster-randomized trial. *Int J Epidemiol* 2015;44:1862-76.
36. Dewey KG, Mridha MK, Matias SL, Arnold CD, Cummins JR, Khan MS, Maalouf-Manasseh Z, Siddiqui Z, Ullah MB, Vosti SA. Lipid-based nutrient supplementation in the first 1000 d improves child growth in Bangladesh: a cluster-randomized effectiveness trial. *Am J Clin Nutr* 2017;105:944-57.
37. Luby SP, Rahman M, Arnold BF, Unicomb L, Ashraf S, Winch PJ, Stewart CP, Begum F, Hussain F, Benjamin-Chung J, et al. Effects of water quality, sanitation, handwashing, and nutritional interventions on diarrhoea and child growth in rural Bangladesh: a cluster randomised controlled trial. *Lancet Glob Health* 2018;6:e302-e15.
38. Hess SY, Abbedou S, Jimenez EY, Some JW, Vosti SA, Ouedraogo ZP, Guissou RM, Ouedraogo JB, Brown KH. Small-quantity lipid-based nutrient supplements, regardless of their zinc content, increase growth and reduce the prevalence of stunting and wasting in young Burkinabe children: a cluster-randomized trial. *PLoS One* 2015;10:e0122242.
39. Becquey E, Huybrechts L, Zongrone A, Le Port A, Leroy JL, Rawat R, Toure M, Ruel MT. Impact on child acute malnutrition of integrating a preventive nutrition package into facility-based screening for acute malnutrition during well-baby consultation: a cluster-randomized controlled trial in Burkina Faso. *PLoS Med* 2019;16:e1002877.
40. Adu-Afarwuah S, Lartey A, Okronipa H, Ashorn P, Peerson JM, Arimond M, Ashorn U, Zeilani M, Vosti S, Dewey KG. Small-quantity, lipid-based nutrient supplements provided to women during pregnancy and 6 mo postpartum and to their infants from 6 mo of age increase the mean attained length of 18-mo-old children in semi-urban Ghana: a randomized controlled trial. *Am J Clin Nutr* 2016;104:797-808.
41. Iannotti LL, Dulience SJ, Green J, Joseph S, Francois J, Antenor ML, Lesorogol C, Mounce J, Nickerson NM. Linear growth increased in young children in an urban slum of Haiti: a randomized controlled trial of a lipid-based nutrient supplement. *Am J Clin Nutr* 2014;99:198-208.
42. Null C, Stewart CP, Pickering AJ, Dentz HN, Arnold BF, Arnold CD, Benjamin-Chung J, Clasen T, Dewey KG, Fernald LCH, et al. Effects of water quality, sanitation, handwashing, and nutritional

- interventions on diarrhoea and child growth in rural Kenya: a cluster-randomised controlled trial. *Lancet Glob Health* 2018;6:e316-e29.
43. Galasso E, Weber AM, Stewart CP, Ratsifandrihamana L, Fernald LCH. Effects of nutritional supplementation and home visiting on growth and development in young children in Madagascar: a cluster-randomised controlled trial. *Lancet Glob Health* 2019;7:e1257-e68.
44. Ashorn P, Alho L, Ashorn U, Cheung YB, Dewey KG, Gondwe A, Harjunmaa U, Lartey A, Phiri N, Phiri TE, et al. Supplementation of maternal diets during pregnancy and for 6 months postpartum and infant diets thereafter with small-quantity lipid-based nutrient supplements does not promote child growth by 18 months of age in rural Malawi: a randomized controlled trial. *J Nutr* 2015;145:1345-53.
45. Maleta KM, Phuka J, Alho L, Cheung YB, Dewey KG, Ashorn U, Phiri N, Phiri TE, Vosti SA, Zeilani M, et al. Provision of 10-40 g/d lipid-based nutrient supplements from 6 to 18 months of age does not prevent linear growth faltering in Malawi. *J Nutr* 2015;145:1909-15.
46. Huybrechts L, Le Port A, Becquey E, Zongrone A, Barba FM, Rawat R, Leroy JL, Ruel MT. Impact on child acute malnutrition of integrating small-quantity lipid-based nutrient supplements into community-level screening for acute malnutrition: a cluster-randomized controlled trial in Mali. *PLoS Med* 2019;16:e1002892.
47. Humphrey JH, Mbuya MNN, Ntozini R, Moulton LH, Stoltzfus RJ, Tavengwa NV, Mutasa K, Majo F, Mutasa B, Mangwadu G, et al. Independent and combined effects of improved water, sanitation, and hygiene, and improved complementary feeding, on child stunting and anaemia in rural Zimbabwe: a cluster-randomised trial. *Lancet Glob Health* 2019;7:e132-e47.
48. Prendergast AJ, Chasekwa B, Evans C, Mutasa K, Mbuya MNN, Stoltzfus RJ, Smith LE, Majo FD, Tavengwa NV, Mutasa B, et al. Independent and combined effects of improved water, sanitation, and hygiene, and improved complementary feeding, on stunting and anaemia among HIV-exposed children in rural Zimbabwe: a cluster-randomised controlled trial. *Lancet Child Adolesc Health* 2019;3:77-90.
49. Smuts CM, Matsungo TM, Malan L, Kruger HS, Rothman M, Kvalsvig JD, Covic N, Joosten K, Osendarp SJM, Bruins MJ, et al. Effect of small-quantity lipid-based nutrient supplements on growth, psychomotor development, iron status, and morbidity among 6- to 12-mo-old infants in South Africa: a randomized controlled trial. *Am J Clin Nutr* 2019;109:55-68.
50. Tam E, Keats EC, Rind F, Das JK, Bhutta AZA. Micronutrient supplementation and fortification interventions on health and development outcomes among children under-five in low- and middle-income countries: a systematic review and meta-analysis. *Nutrients* 2020;12:289.
51. Arikpo D, Edet ES, Chibuzor MT, Odey F, Caldwell DM. Educational interventions for improving primary caregiver complementary feeding practices for children aged 24 months and under. *Cochrane Database Syst Rev* 2018;5:CD011768.
52. Matsuyama M, Harb T, David M, Davies PS, Hill RJ. Effect of fortified milk on growth and nutritional status in young children: a systematic review and meta-analysis. *Public Health Nutr* 2017;20:1214-25.
53. Sguassero Y, de Onis M, Bonotti AM, Carroli G. Community-based supplementary feeding for promoting the growth of children under five years of age in low and middle income countries. *Cochrane Database Syst Rev* 2012;6:CD005039.
54. Eichler K, Wieser S, Ruthemann I, Brugger U. Effects of micronutrient fortified milk and cereal food for infants and children: a systematic review. *BMC Public Health* 2012;12:506.
55. Suchdev PS, Jefferds MED, Ota E, da Silva Lopes K, De-Regil LM. Home fortification of foods with multiple micronutrient powders for health and nutrition in children under two years of age. *Cochrane Database Syst Rev* 2020;2:CD008959.

56. Prado EL, Larson LM, Cox K, Bettencourt K, Kubes JN, Shankar AH. Do effects of early life interventions on linear growth correspond to effects on neurobehavioural development? A systematic review and meta-analysis. *Lancet Glob Health* 2019;7:e1398-e413.
57. Aboud FE, Yousafzai AK. Global health and development in early childhood. *Annu Rev Psychol* 2015;66:433-57.
58. Wells JC. Natural selection and sex differences in morbidity and mortality in early life. *J Theor Biol* 2000;202:65-76.
59. Wachs TD, Rahman A. The nature and impact of risk and protective influences on children's development in low-income countries. In P. R. Britto, P. L. Engle & C. M. Super (Eds.), *Handbook of early childhood development research and its impact on global policy* (pp. 85-122). New York: Oxford University Press. 2013.
60. Nemeth E, Ganz T. The role of hepcidin in iron metabolism. *Acta Haematol* 2009;122:78-86.
61. Hurrell RF. Influence of inflammatory disorders and infection on iron absorption and efficacy of iron-fortified foods. *Nestle Nutr Inst Workshop Ser* 2012;70:107-16.
62. Every Woman Every Child. The global strategy for women's, children's and adolescent's health (2016-2030). 2015. Available at: <http://www.globalstrategy.everywomaneverychild.org>. Accessed on: 26 January 2021.
63. World Malaria Report 2018. Geneva: World Health Organization; 2018. Available at: <https://www.who.int/malaria/publications/world-malaria-report-2018/report/en/> Accessed on: 26 August 2019.
64. WHO, UNICEF Joint Monitoring Programme. Drinking Water. Available at <http://washdata.org/monitoring/drinking-water>. Accessed on: 26 August 2019.
65. WHO, UNICEF Joint Monitoring Programme. Sanitation. Available at <http://washdata.org/monitoring/sanitation>. Accessed on: 26 August 2019.

**Box 1. Eligibility criteria for the SQ-LNS individual participant data (IPD) analyses**

**Inclusion criteria**

- Randomized controlled trial
- Conducted in low- or middle-income country
- SQ-LNS (<~125 kcal/d) provided to the intervention group for at least 3 mo between 6 and 24 mo of age
- At least one trial group did not receive SQ-LNS or other type of child supplementation
- Longitudinal follow-up of each child, or repeated cross-sectional data collection
- Individual children eligible for IPD analysis if:
  - Age at baseline allowed receipt of intervention (supplementation or control group components) for at least 3 mo between 6 and 24 mo of age.
  - For anemia & micronutrient status outcomes, blood samples were collected during the supplementation period or within 3 mo after the study-defined end of supplementation.

**Exclusion criteria**

- LNS was used for treatment, not prevention, of malnutrition (i.e., only children with severe or moderate malnutrition were eligible for the study)
- Conducted in a hospitalized population or among children with a pre-existing disease
- SQ-LNS provision was combined with additional supplemental food or nutrients within a single arm (e.g. SQ-LNS + food rations vs. control), and there was no appropriate comparison group that would allow isolation of the SQ-LNS effect (e.g., food rations alone)

**Table 1: Potential effect modifiers considered within each outcome domain**

	<b>Growth</b>	<b>Development</b>	<b>Biomarkers</b>
<b><i>Study-level effect modifiers</i></b>			
Geographic region (African vs. South-East Asia Region)	✓	✓	✓
Stunting burden (study-specific control group at 18 mo of age: $\geq 35\%$ vs. $< 35\%$ )	✓	✓	
Anemia burden (country-specific: $< 60\%$ vs. $\geq 60\%$ ) <sup>1</sup>		✓	✓
Malaria prevalence (country-specific: $< 10\%$ vs. $\geq 10\%$ ) <sup>2</sup>	✓	✓	✓
Inflammation prevalence (study-specific: elevated CRP $\leq 25\%$ and/or elevated AGP $\leq 50\%$ vs. elevated CRP $> 25\%$ and/or elevated AGP $> 50\%$ ) <sup>3</sup>			✓
Source water quality (study-specific: $< 75\%$ vs. $\geq 75\%$ prevalence of improved drinking water) <sup>4</sup>	✓	✓	✓
Sanitation (study-specific: $< 50\%$ vs. $\geq 50\%$ prevalence of improved sanitation) <sup>4</sup>	✓	✓	✓
Duration of child supplementation (study target: $> 12$ mo vs. $\leq 12$ mo)	✓	✓	✓
Iron dose in the SQ-LNS product (9 mg/d vs. $< 9$ mg/d)			✓
Child age at baseline or endline	✓	✓	✓
Frequency of contact for intervention delivery or outcome assessments (weekly vs. monthly)	✓	✓	✓
Compliance (study-defined average percent compliance in LNS group $\geq 80\%$ vs. $< 80\%$ )	✓	✓	✓
<b><i>Individual-level effect modifiers</i></b>			
Maternal height ( $< 150.1$ cm vs. $\geq 150.1$ cm) <sup>5</sup>	✓	✓	
Maternal BMI ( $< 20 \text{ kg/m}^2$ vs. $\geq 20 \text{ kg/m}^2$ )	✓	✓	✓
Maternal age ( $< 25$ y vs. $\geq 25$ y)	✓	✓	✓
Maternal education (no formal or incomplete primary vs. complete primary or greater)	✓	✓	✓
Maternal depressive symptoms ( $< 75^{\text{th}}$ percentile vs. $\geq 75^{\text{th}}$ percentile within the study sample)	✓	✓	
Child sex (female vs. male)	✓	✓	✓
Child birth order (first born vs. later born)	✓	✓	✓
Child baseline anthropometric status (lower vs. higher z-score) <sup>6</sup>	✓	✓	✓
Child baseline anemia status (hemoglobin $\geq 110 \text{ g/L}$ vs. $< 110 \text{ g/L}$ )		✓	✓
Child high-dose vitamin A supplementation (receipt within 6mo prior to outcome assessment vs. non-receipt)			✓
Child inflammation at time of outcome assessment (CRP $\leq 5 \text{ mg/L}$ and AGP $\leq 1 \text{ g/L}$ vs. not)			✓
Household socio-economic status ( $<$ median vs. $\geq$ median study-defined asset index)	✓	✓	✓
Household food security (study-defined moderate to severe food insecurity vs. mild to secure)	✓	✓	✓
Household source water quality (unimproved vs. improved) <sup>4</sup>	✓	✓	✓
Household sanitation (unimproved vs. improved) <sup>4</sup>	✓	✓	✓
Home environment ( $<$ study median vs. $\geq$ study median) <sup>7</sup>	✓	✓	
Season at the time of outcome assessment (rainy vs. dry) <sup>8</sup>	✓	✓	✓

AGP,  $\alpha$ -1-acid glycoprotein; BMI, body mass index; CRP, C-reactive protein; HCZ, head circumference-for-age z-score; LAZ, length-for-age z-score; LNS, lipid-based nutrient supplements; MUAC, mid-upper arm circumference; MUACZ, mid-upper arm circumference z-score; SQ-LNS, small-quantity lipid-based nutrient supplements; WAZ, weight-for-age z-score; WLZ, weight-for-length z-score

<sup>1</sup> Country-specific prevalence of anemia among children 6-59 months, based on national surveys closest in time to the study

<sup>2</sup> Country-specific prevalence of malaria closest in time to the study, based on World Malaria Report 2018 (63)

<sup>3</sup> Elevated CRP defined as > 5 mg/L, elevated AGP defined as > 1 g/L

<sup>4</sup> Improved drinking water and sanitation quality defined using WHO/UNICEF Joint Monitoring Programme definitions (64, 65)

<sup>5</sup> Cutoff based on -2 SD for height at 19 years of age at [https://www.who.int/growthref/hfa\\_girls\\_5\\_19years\\_z.pdf?ua=1](https://www.who.int/growthref/hfa_girls_5_19years_z.pdf?ua=1)

<sup>6</sup> For the growth domain, this was defined as LAZ < vs.  $\geq$  -1 when LAZ or stunting was the outcome; WLZ < vs.  $\geq$  0 when WLZ, wasting or acute malnutrition was the outcome; MUACZ < vs.  $\geq$  0 when MUACZ or low MUAC was the outcome; WAZ < vs.  $\geq$  -1 when WAZ or underweight was the outcome; HCZ < vs.  $\geq$  -1 when HCZ or small head size was the outcome. For the development domain, this was defined as LAZ < vs.  $\geq$  -2 for all outcomes. For the anemia and micronutrient status domain this was defined as WLZ < -2 or MUAC < 125 mm vs. WLZ  $\geq$  -2 and MUAC  $\geq$  125 mm; if MUAC not measured, WLZ < vs.  $\geq$  -2.

<sup>7</sup> As measured by the Family Care Indicators, Home Observation for the Measurement of the Environment Inventory, or other similar tools

<sup>8</sup> Based on average rainfall during the month of outcome assessment and two months prior.

**Table 2. Characteristics of the trials included in the SQ-LNS individual participant data (IPD) meta-analyses**

Country	Author	Trial name	Infant SQ-LNS		Maternal LNS	Participants
			Age at start (mo)	Duration (mo)		
Bangladesh	Christian 2015 (35)	JiVitA-4	6	12	N	4218
Bangladesh	Dewey 2017 (36)	RDNS	6	18	Y/N	2478
Bangladesh	Luby 2018 (37)	WASH-B-B	6	18	N	4633
Burkina Faso	Hess 2015 (38)	iLiNS-ZINC	9	9	N	2626
Burkina Faso	Becquey 2019 (39)	PROMIS-BF	6	12	N	2651
Ghana	Adu-Afarwuah 2007 (29)		6	6	N	194
Ghana	Adu-Afarwuah 2016 (40)	iLiNS-DYAD-G	6	12	Y	1040
Haiti	Iannotti 2014 (41)		6-11	3-6	N	300
Kenya	Null 2018 (42)	WASH-B-K	6	18	N	6649
Madagascar	Galasso 2019 (43)	MAHAY	6-11	6-12	Y/N	3390
Malawi	Ashorn 2015 (44)	iLiNS-DYAD-M	6	12	Y	664
Malawi	Maleta 2015 (45)	iLiNS-DOSE	6	12	N	943
Mali	Huybrechts 2019 (46)	PROMIS-M	6	18	N	2937
Zimbabwe	Humphrey 2019 (47)	SHINE	6	12	N	3676
Zimbabwe	Prendergast 2019 (48)	SHINE (HIV-exp)	6	12	N	667

**Table 3. Relative reductions in adverse outcomes<sup>1</sup> in meta-analyses of intervention trials providing SQ-LNS to children 6-24 mo of age**

<b>Growth outcomes</b>	<b>Relative reduction (95% CI) %</b>
Stunting (LAZ < -2 SD)	12 (9, 15) %
Wasting (WLZ < -2 SD)	14 (7, 20) %
Underweight (WAZ < -2 SD)	13 (9, 17) %
Acute malnutrition (WLZ < -2 SD or MUAC < 125 mm)	14 (7, 20) %
Low MUAC (MUACZ < -2 SD or MUAC < 125 mm)	18 (11, 25) %
Small head circumference (HCZ < -2 SD)	9 (5, 14) %
<b>Development outcomes<sup>2</sup></b>	
Low language development score	16 (8, 24) %
Low motor development score	16 (8, 24) %
Low social-emotional development score	19 (11, 26) %
<b>Anemia &amp; micronutrient status outcomes</b>	
Anemia (Hb < 110 g/L)	16 (13, 19) %
Moderate-severe anemia (Hb < 100 g/L)	28 (24, 32) %
Iron deficiency (Ferritin < 12 µg/L)	56 (50, 61) %
Iron deficiency anemia (Hb < 110 g/L and ferritin < 12 µg/L)	64 (56, 70) %
Vitamin A deficiency (RBP < 0.70 µmol/L)	56 (30, 73) %
<b>Mortality</b>	27 (11, 41) %

Hb, hemoglobin; HCZ, head circumference-for-age z-score; LAZ, length-for-age z-score; MUAC, mid-upper arm circumference; MUACZ, mid-upper arm circumference z-score; RBP, retinol binding protein; SQ-LNS, small-quantity lipid-based nutrient supplements; WAZ, weight-for-age z-score; WLZ, weight-for-length z-score

<sup>1</sup> Based on Dewey et al. ((23), growth outcomes), Prado et al. ((24), development outcomes), Wessells et al. ((25), anemia and micronutrient status outcomes), and Stewart et al. ((22), mortality).


<sup>2</sup> Lowest decile defined for each study based on the within-study distribution.

## Figure Legends

Figure 1: Illustration of the concepts of potential to benefit and potential to respond. A: Subgroup a-1 has greater nutritional deficits, here illustrated as being slightly smaller and thinner than subgroup a-2, and therefore has a greater potential to benefit from a nutritional intervention. B: Subgroup b-1 has a greater potential to respond to a nutritional intervention, due to fewer constraints, as compared to subgroup b-2. SQ-LNS, small-quantity lipid-based nutrient supplements.

Figure 2: Illustration of the cutoff effect. The intervention shifts both subgroup distributions similarly, resulting in a higher proportion of the individuals in subgroup B crossing the cutoff value threshold. SQ-LNS, small-quantity lipid-based nutrient supplements.

## A: Potential to benefit



## B: Potential to respond

